We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ANAB market cap is 432.39M. The company's latest EPS is USD -5.3771 and P/E is -2.65.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 3.32M | 9.01M | 7.18M | 10.97M | 30.02M |
| Operating Income | -37.73M | -42.14M | -42.2M | -40.32M | -22.76M |
| Net Income | -37.31M | -42.21M | -43.94M | -46.66M | -32.85M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 8M | 75M | 63.18M | 10.29M | 17.16M |
| Operating Income | -107.43M | -23.88M | -56.81M | -115.15M | -164.41M |
| Net Income | -97.34M | -19.93M | -57.8M | -128.72M | -163.62M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 487.33M | 452.39M | 405.84M | 427.38M | 493.42M |
| Total Liabilities | 366.94M | 364.29M | 358.06M | 417.5M | 409.05M |
| Total Equity | 120.38M | 88.1M | 47.78M | 9.88M | 84.37M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 435.2M | 416.55M | 643.07M | 610.38M | 452.39M |
| Total Liabilities | 30.19M | 19.82M | 286.64M | 348.28M | 364.29M |
| Total Equity | 405.01M | 396.73M | 356.43M | 262.1M | 88.1M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -86.45M | -120.8M | -37.25M | -58.58M | -68.67M |
| Investing | 95.58M | 144.75M | 68.62M | 66.17M | 124.79M |
| Financing | -54.14M | -59.3M | -13.63M | 28.26M | 99.49M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -69.52M | -14.16M | -45.92M | -73.59M | -120.8M |
| Investing | 131.43M | 94.48M | 38.84M | -394.85M | 144.75M |
| Financing | -4.49M | -879k | 252.3M | 44.02M | -59.3M |
| Market Cap | 432.39M |
| Price to Earnings Ratio | -2.65 |
| Price to Sales Ratio | 25.27 |
| Price to Cash Ratio | 12.06 |
| Price to Book Ratio | 4.92 |
| Dividend Yield | - |
| Shares Outstanding | 30.43M |
| Average Volume (1 week) | 685.6k |
| Average Volume (1 Month) | 614.67k |
| 52 Week Change | -37.81% |
| 52 Week High | 41.3083 |
| 52 Week Low | 12.51 |
| Spread (Intraday) | 6.05 (30.25%) |
| Company Name | AnaptysBio Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.anaptysbio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
